Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Core Viewpoint - Theravance Biopharma, Inc. is set to report its fourth quarter and full year 2024 financial results on February 26, 2025, along with a business update [1] Company Overview - Theravance Biopharma focuses on delivering impactful medicines, leveraging decades of expertise [3] - The company has developed the FDA-approved YUPELRI® (revefenacin) inhalation solution for chronic obstructive pulmonary disease (COPD) [3] - Ampreloxetine, a late-stage investigational drug, is being developed for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA) [3] - The company aims to create and drive shareholder value [3]